FDA Issues Draft Guidance to Accelerate Personalized Gene Therapy Development
The U.S. Food and Drug Administration (FDA) has released new draft guidance aimed at streamlining the regulatory pathway for personalized gene therapies targeting rare diseases. This initiative responds to industry requests for clearer frameworks regarding how developers can obtain approval for highly individualized treatments that may vary significantly between patients. The move is intended to reduce regulatory uncertainty for biotechnology sponsors, potentially accelerating the time-to-market for life-saving genetic interventions. By providing a structured approach to development and manufacturing requirements, the FDA seeks to foster innovation in the niche sector of precision medicine.
Tickers: $RARE
Topics: Drug Development Gene Therapy Personalized Medicine Rare Disease